Results 141 to 150 of about 1,705,592 (288)
Biotechnology and Bioengineering, EarlyView.Lifecycle perspective on cell and gene therapy manufacturing challenges and enabling GMP solutions. ABSTRACT Cell and gene therapies (CGTs) are revolutionizing modern medicine; however, making these advanced medicines scalable and readily available to commercial manufacturers worldwide is a major challenge. The number of approved CGT products continues
Rajath Samaga +2 more
wiley +1 more source
The HLA class I immunopeptidomes of AAV capsid proteins. [PDF]
Front Immunol, 2023 Brito-Sierra CA +3 more
europepmc +1 more source
Nuclear Transport of the Major Capsid Proteins Is Essential for Adeno-Associated Virus Capsid Formation [PDF]
Adeno-associated virus capsids are composed of three proteins, VP1, VP2, and VP3. Although VP1 is necessary for viral infection, it is not essential for capsid formation.
7165 +21 more
core +1 more source
Amino acid substitutions in FMDV capsid surface proteins.
, 2019 Amino acid substitutions in FMDV capsid surface proteins.
Patrick S. Chain (163435) +9 more
core +1 more source
RNA‐centric world of retroviruses: unravelling the molecular strategies of genomic RNA packaging
Biological Reviews, EarlyView.ABSTRACT Retroviruses constitute a unique group of RNA viruses that have profoundly influenced both evolutionary trajectories and biomedical research. Their ability to reverse transcribe and integrate into host genomes has shaped genomic architecture across species and contributed to our understanding of oncogenes, gene regulation, and RNA biology ...
Mohammad Abdullah Jehad +5 more
wiley +1 more source
Status and future of recombinant adeno‐associated virus vector manufacturing
Biotechnology Progress, EarlyView.Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley +1 more source
Demonstration of nanofiltration‐based virus safety for AAV manufacturing using model viruses
Biotechnology Progress, EarlyView.Abstract Virus safety for biopharmaceutical products has been a well‐established concern for several decades. While various virus reduction steps have been identified and implemented for traditional plasma‐derived and monoclonal antibody products, there are various challenges to achieving the same virus safety in emerging gene therapy products.
Brian Buesing +2 more
wiley +1 more source
Biotechnology Progress, EarlyView.High‐throughput anion‐exchange chromatography process development enables scalable purification of high‐purity recombinant adeno‐associated virus capsids. Abstract Recombinant adeno‐associated virus (rAAV) production commonly yields a high proportion of empty and partially filled capsids, necessitating downstream purification to enrich full capsids ...
Kevin Vera +8 more
wiley +1 more source
Biotechnology Progress, EarlyView.Abstract Recombinant adeno‐associated virus production for gene therapy applications commonly relies on the Spodoptera frugiperda 9 (Sf9) baculovirus infection platform. The process encompasses cell expansion from flasks through intermediate‐scale bioreactors to large‐scale production.
Min Tae Park, Seyed Pouria Motevalian
wiley +1 more source